Potential Biomarker, Drug Target ID’d for Adult Leukemia
Tumors from adults with B-cell precursor acute lymphoblastic leukemia have epigenetic changes.
Diagnosis & Disease Information
Synribo Approved for Chronic Myeloid Leukemia
Teva Pharmaceuticals announced that the FDA has approved Synribo (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).
Better Prognosis for Early Blast Clearance in Leukemia
AML patients whose peripheral blasts clear six days or less after chemotherapy have better survival
NDA Accepted, Priority Review Granted for Ponatinib for CML and Ph+ ALL
ARIAD Pharmaceuticals announced that the FDA has accepted for filing the New Drug Application (NDA) of ponatinib for patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL); the FDA also has granted ARIAD’s request for Priority Review.
AACR: Longer Formula Feeding, Delayed Introduction of Solid Foods, Increase Pediatric ALL Risk
The longer a child is fed formula and the later the age solid foods are introduced, the greater the risk for developing acute lymphoblastic leukemia.
New Cellular Assay Predicts Leukemia Cells’ Responses to Chemotherapy
A new profiling technique determines acute myeloid leukemia (AML) cells’ “readiness” for apoptotic cell death – and hence, their likely responses to chemotherapy.
CVT-E002 Reduces Rates of Moderate to Severe Acute Respiratory Illness in Patients with CLL
Treating patients with chronic lymphocytic leukemia (CLL) with a proprietary extract of Panax quinquefolius, CVT-E002, resulted in a trend toward reduced rates of moderate to severe acute respiratory illness (ARI); however, the agent did not significantly reduce ARI days or antibiotic use.
Novel Assay May Further Individualize Treatment for AML
Information provided by BH3 profiling, an assay of mitochondrial apoptotic function, can “potentially be exploited” to personalize therapy for patients with acute myelogenous leukemia.
HIV Status Doesn’t Influence Hodgkin Lymphoma Outcome
In HIV-positive patients with Hodgkin lymphoma treated with ABVD chemotherapy, despite more extensive disease, worse prognosis but not worse outcome.
Hodgkin Lymphoma Treatment Reduces Likelihood of Parenthood by 24%
Survivors of Hodgkin lymphoma had significantly fewer children after treatment than matched population controls.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...